TrialPath
Recruiting

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290 · Black Diamond Therapeutics, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
About this study
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
Eligibility criteria
Phase 2 Eligibility: Key Inclusion Criteria Required for locally advanced or metastatic NSCLC: * Measurable disease by RECIST 1.1 criteria. * Adequate bone marrow or organ function. * Life expectancy of ≥ 3 months. * Sufficient performance status. * Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases. * Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort): * Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable). * Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib). * Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. * Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET): * Non-classical driver EGFR mutations (eg, L861R, S768I, G719X). * EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI. * For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis. Key Exclusion Criteria: * Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET). * Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC. * Any history of interstitial lung disease related to EGFR TKI use. * Symptomatic or radiographic leptomeningeal disease. * Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention. * Unresolved toxicity from prior therapy. * Significant cardiovascular disease. * Major surgery within 4 weeks of study entry or planned during study. * Ongoing or recent anticancer therapy or radiation therapy. * Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years. * Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier. * Poorly controlled gastrointestinal disorders.
Study design
Enrollment target: 220 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2022-03-31
Estimated completion: 2028-06
Last updated: 2026-11-18
Interventions
Drug: silevertinib monotherapy
Primary outcomes
  • • Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535) (The first treatment 21-day cycle (Cycle 1))
  • • Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535) (Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days))
  • • Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose (Through study completion, approximately 1 year)
Sponsor
Black Diamond Therapeutics, Inc. · industry
Contacts & investigators
ContactBDTX Clinical Trial Navigation Service · contact · blackdiamondtx@careboxhealth.com · (866) 955-4397
InvestigatorBlack Diamond Therapeutics · study_director, Black Diamond Therapeutics
All locations (19)
University of AlabamaRecruiting
Birmingham, Alabama, United States
Banner MD Anderson Cancer CenterRecruiting
Gilbert, Arizona, United States
City of Hope Orange County Lennar Foundation Cancer CenterRecruiting
Irvine, California, United States
Cedars Sinai Medical CenterRecruiting
Los Angeles, California, United States
Sibley Memorial Hospital Johns Hopkins MedicineRecruiting
Washington D.C., District of Columbia, United States
Mayo Clinic- JacksonvilleRecruiting
Jacksonville, Florida, United States
Miami Cancer Institute - Baptist Health South FloridaRecruiting
Miami, Florida, United States
UHP- University of Hawaii Cancer CenterRecruiting
Honolulu, Hawaii, United States
Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityRecruiting
Chicago, Illinois, United States
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
Mayo Clinic- RochesterRecruiting
Rochester, Minnesota, United States
Montefiore Medical CenterRecruiting
The Bronx, New York, United States
University of Pittsburgh Medical Center - Hillman Cancer CenterRecruiting
Pittsburgh, Pennsylvania, United States
Tennessee OncologyRecruiting
Nashville, Tennessee, United States
Inova Schar Cancer InstituteRecruiting
Fairfax, Virginia, United States
Next OncologyRecruiting
Fairfax, Virginia, United States
Fred Hutchinson Cancer Center/University of WashingtonRecruiting
Seattle, Washington, United States
BC Cancer VancouverRecruiting
Vancouver, British Columbia, Canada
The Princess Margaret Cancer CentreRecruiting
Toronto, Ontario, Canada
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations · TrialPath